Another strategy related to CAR construct design is our modeling and engineering of low-affinity variants of our PD-L1 antibody that will spare normal tissues with low levels of antigen expression yet retain binding affinity to target tumor cells that overexpress antigen. This evidence concerns the gene CD274 and neoplasm.